Insilico Medicine, Mabwell Bioscience, and ChemExpress Forging Ahead with ADC Innovation Through Strategic Collaboration (IMAGE)

InSilico Medicine

Insilico Medicine, Mabwell Bioscience, and ChemExpress Forging Ahead with ADC Innovation Through Strategic Collaboration

Caption

The collaboration achieves synergy across the entire value chain from AI-driven design and antibody development to payload-linker chemical synthesis and clinical development, establishing a complete, closed-loop value chain for ADC development, and maximizes the advantage of all parties, driving innovation and development of ADCs efficiently and effectively to provide more treatment options for patients worldwide.

Credit

Insilico Medicine, Mabwell Bioscience, and ChemExpress

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.